Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future

Y Zhang, H Chen, R Li, K Sterling… - Signal transduction and …, 2023 - nature.com
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

NM Moussa‐Pacha, SM Abdin, HA Omar… - Medicinal research …, 2020 - Wiley Online Library
Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder
with no current cure. One of the important therapeutic approaches of AD is the inhibition of β …

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies

P Sharma, P Srivastava, A Seth, PN Tripathi… - Progress in …, 2019 - Elsevier
AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

[HTML][HTML] The use of spirocyclic scaffolds in drug discovery

Y Zheng, CM Tice, SB Singh - Bioorganic & Medicinal Chemistry Letters, 2014 - Elsevier
Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have
been increasingly utilized in drug discovery. In this brief review, we highlight selected …

CNS drug design: balancing physicochemical properties for optimal brain exposure

Z Rankovic - Journal of medicinal chemistry, 2015 - ACS Publications
The human brain is a uniquely complex organ, which has evolved a sophisticated protection
system to prevent injury from external insults and toxins. Designing molecules that can …

Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside

F Islam, MH Nafady, MR Islam, S Saha, S Rashid… - Molecular …, 2022 - Springer
Alzheimer's disease (AD) is the most common cause of dementia and cognitive impairment;
yet, there is currently no treatment. A buildup of Aβ, tau protein phosphorylation, oxidative …

A close look at BACE1 inhibitors for Alzheimer's disease treatment

B Das, R Yan - CNS drugs, 2019 - Springer
Abstract Alzheimer's disease (AD), the most common cause of age-dependent dementia, is
one of the most significant healthcare problems worldwide. Aggravating this situation, drugs …

The utilization of spirocyclic scaffolds in novel drug discovery

YJ Zheng, CM Tice - Expert opinion on drug discovery, 2016 - Taylor & Francis
Spirocycles are ring systems in which two rings are fused through a single atom, referred to
as the spiro atom. The ethylene glycol ketal of cyclohexanone is an example of a well-known …

Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease

K Rajasekhar, M Chakrabarti… - Chemical …, 2015 - pubs.rsc.org
Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid
protein is invariably misfolded and deposited in cells and organs. Alzheimer's disease is one …

Highlights in BACE1 inhibitors for Alzheimer's disease treatment

JRM Coimbra, DFF Marques, SJ Baptista… - Frontiers in …, 2018 - frontiersin.org
Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common
type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of …